AstraZeneca’s (AZN) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by Deutsche Bank Aktiengesellschaft in a report released on Tuesday, Marketbeat reports. They presently have a £105 ($129.69) target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential downside of 7.51% from the company’s current price.

A number of other research firms have also recently issued reports on AZN. Barclays restated an “overweight” rating and set a £125 ($154.40) price objective on shares of AstraZeneca in a research report on Monday, April 8th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Monday, April 15th. Jefferies Financial Group restated a “hold” rating and set a £110 ($135.87) price objective on shares of AstraZeneca in a research report on Friday, February 16th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Thursday, April 4th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of AstraZeneca in a research report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of £116.86 ($144.34).

AstraZeneca Stock Up 0.7 %

AZN opened at £113.52 ($140.22) on Tuesday. AstraZeneca has a twelve month low of GBX 9,461 ($116.86) and a twelve month high of £123.48 ($152.52). The firm has a market cap of £175.96 billion, a P/E ratio of 3,746.53, a price-to-earnings-growth ratio of 0.89 and a beta of 0.19. The business has a 50 day moving average price of £104.96 and a 200 day moving average price of £104.33. The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.